Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.95 CHF | +1.94% | +12.00% | +156.73% |
04-24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
04-17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.86M 27.12M | Sales 2023 | 33.56M 37.06M 50.61M | Capitalization | 128M 142M 193M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.46M -21.11M | Net income 2023 | -13M -14.36M -19.6M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.39M 33.3M | Net cash position 2023 | 12M 13.25M 18.09M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.77% |
1 day | +1.94% | ||
1 week | +12.00% | ||
Current month | +38.27% | ||
1 month | +37.21% | ||
3 months | +67.16% | ||
6 months | +114.87% | ||
Current year | +156.73% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 8.96 | +2.05% | 49 442 |
24-05-30 | 8.78 | +7.07% | 354,168 |
24-05-29 | 8.2 | -3.53% | 155,663 |
24-05-28 | 8.5 | +4.94% | 447,957 |
24-05-27 | 8.1 | +1.25% | 79,384 |
Delayed Quote Swiss Exchange, May 31, 2024 at 04:22 am
More quotes1st Jan change | Capi. | |
---|---|---|
+156.73% | 359M | |
+8.92% | 114B | |
+10.48% | 105B | |
-3.29% | 21.73B | |
-6.45% | 23.83B | |
-10.67% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- KURN Stock